RUNX2 and skeletal dysplasia: Conversely, inhibitors or insufficient transactivators may decrease Col10a1 expression and delay chondrocyte maturation and thus contribute to low bone growth as seen in skeletal dysplasia, or less cartilage degradation as seen in Runx2+/− mice of an OA mouse model (Zhu et al., 2017).